Page last updated: 2024-11-05

pentaerythritol tetranitrate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pentaerythritol Tetranitrate: A vasodilator with general properties similar to NITROGLYCERIN but with a more prolonged duration of action. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1025) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pentaerythritol tetranitrate : A pentaerythritol nitrate in which all four hydroxy groups of pentaerythritol have been converted to the corresponding nitrate ester. It is a vasodilator with properties similar to those of glyceryl trinitrate, but with a more prolonged duration of action, and is used for treatment of angina pectoris. It is also one of the most powerful high explosives known and is a component of the plastic explosive known as Semtex. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6518
CHEMBL ID466659
CHEBI ID25879
SCHEMBL ID37177
MeSH IDM0016166

Synonyms (184)

Synonym
petn
pentaerythritol tetranitrate
1,3-propanediol, 2,2-bis[(nitrooxy)methyl]-, dinitrate (ester)
quintrate
C0051
pentaerithrityl tetranitrate
perityl
deltrate-20
petn, nf
nitropentaerythritol
1,3-propanediol, 2,2-bis[(nitrooxy)methyl]-, dinitrate (ester)
chot
2,2-bis(hydroxymethyl)-1,3-propanediol tetranitrate
peridex-la
baritrate
pentaerythrite tetranitrate
nitropentaerythrite
penthrit
1,3-dinitrato-2,2-bis(nitratomethyl)propane
antora
angicap
vasodiatol
pentaerythritol tetranitrate with 80% d-lactose monohydrate
2,2-bisdihydroxymethyl-1,3-propanediol tetranitrate
pentaerythrityl tetranitrate
pentaerythrite tetranitrate (dry) [forbidden]
deltrate 20
lx 02-1
einecs 201-084-3
dilcoran 80
hsdb 6313
niperyt
vaso-80 unicelies
xtx 8003
dipentrate
rythritol
nitrinol
vasitol
erinit
hasethrol
pen-tetra
na0150 ,
extex
nitrotalans
pentaerythrite tetranitrate, with not < 7% water, by mass
lx 08-0
kaytrate
tanipent
tetrasule
pentaerythritylium tetranitricum
pentritol
nitropenta 7w
neo-corovas
pentetrate unicelles
sdm no. 23
lentrat
pentanitrolum
pentrite
pentriol
lx 13
prevangor
mycardol
pentanitrine
pentitrate
pentanitrol
myotrate 10
erynitum
nitrinal
pbxn 301
pentaerythritol nitrate
pentarit
dilcoran-80
cardiacap
tetranitrate de pentaerythrityle
pentaerythritol tetranitrate, diluted
penthrite
un0411
brn 1716886
pergitral
c 2 (explosive)
pentaerithrityli tetranitras [inn-latin]
tetranitropentaerythrite
tranite d-lay
1,3-propanediol, 2,2-bis((nitrooxy)methyl)-, dinitrate (ester)
tetranitrato de pentaeritritilo [inn-spanish]
el petn
pentaeritrile tetranitrato [dcit]
pentaerythritol, tetranitrate
pentritol tempules
terpate
metranil
pentaerythrite tetranitrate, wetted with not < 25% water, by mass or desensitized with not < 15% phlegmatizer, by mass
ccris 2387
pentryate 80
pentrate
neopentanetetrayl nitrate
tetranitrate de pentaerithrityle [inn-french]
nitropenton
pencard
nitropenta
pentestan-80
lowetrate
niperyth
nitro-riletten
nci-c55743
pentral 80
pentafin
2,2-bis((nitrooxy)methyl)-1,3-propanediol dinitrate (ester)
angitet
lx 16 (explosive)
arcotrate
duotrate
pentryate
martrate-45
peritrate
subicard
nitrolong
vaso-80
mikardol
nitropent
tentrate-20
martrate 45
NCGC00159388-02
pentaerithrityl tetranitrate (inn)
pentaerythritol tetranitrate (jan)
pentritol tempules (tn)
78-11-5
D01721
NCGC00159388-03
[3-nitrooxy-2,2-bis(nitrooxymethyl)propyl] nitrate
pentaerithritol tetranitrate
pentalong
chebi:25879 ,
CHEMBL466659
NCGC00159388-04
tetranitrato de pentaeritritilo
10l39trg1z ,
pentaeritrile tetranitrato
pentaerithrityli tetranitras
pentaerithrityl tetranitrate [inn]
pent
ec 201-084-3
ten [vasodilator]
tetranitrate de pentaerithrityle
pentaerythrite tetranitrate or pentaerythritol tetranitrate or petn, wetted with not <25% water, by mass or pentaerythrite tetranitrate or pentaerythritol tetranitrate or petn, desensitized with not <15% phlegmatizer by mass
unii-10l39trg1z
corpent
pentaerythritol tetranitrate [usp:jan]
pentaerythrite tetranitrate or pentaerythritol tetranitrate or petn, wetted with not <25% water, by mass or pentaerythrite tetranitrate or pentaerythritol tetranitrate or petn, desensitized with not <15% phlegmatizer by mass [na0150] [explosive 1.1a]
pentaerythrite tetranitrate (dry)
1,3-propanediol, 2,2-bis((nitrooxy)methyl)-, 1,3-dinitrate
4-01-00-02816 (beilstein handbook reference)
NCGC00255290-01
cas-78-11-5
dtxsid2023430 ,
dtxcid901109
tox21_301747
tox21_111624
2,2-bis((nitrooxy)methyl)-1,3-propanediol dinitrate
3-(nitrooxy)-2,2-bis[(nitrooxy)methyl]propyl nitrate
2,2-bis((nitrooxy)methyl)-1,3-propanediol dinitrate ester
tetranitropentaerythritol
pentaerythritol tetranitrate [vandf]
pentaerythritol tetranitrate [jan]
pentaerithrityl tetranitrate [who-dd]
pentaerythritol tetranitrate [hsdb]
pentaerithrityl tetranitrate [mart.]
pentaerythritol tetranitrate [mi]
SCHEMBL37177
NCGC00159388-05
2,2-bis[(nitrooxy)methyl]-1,3-propanediol dinitrate (ester)
pentafilin
1,3-propanediol, 2,2-bis[(nitrooxy)methyl]-, dinitrate
sdm no. 35 (salt/mix)
p.e.t.n.
miltrate (salt/mix)
sdm no. 23 (salt/mix)
vaso-80 unicelles
pentrinat
pentaerythritoltetranitrate
DB06154
Q189334
2,2-bis(hydroxy-methyl)-1,3-propanediol tetranitrate
EN300-18536597

Research Excerpts

Overview

Pentaerythritol tetranitrate (PETN) is a nitrate ester explosive that may be persistent with scarce reports on its environmental fate and impacts. PETN is an organic nitrate that has been used in the therapy of angina.

ExcerptReferenceRelevance
"Pentaerythritol tetranitrate (PETN) is a nitrate ester explosive that may be persistent with scarce reports on its environmental fate and impacts. "( Bacteria isolated from explosive contaminated environments transform pentaerythritol tetranitrate (PETN) under aerobic and anaerobic conditions.
Arbeli, Z; Avila-Arias, H; Benavides López de Mesa, J; Carvajal Ramirez, S; Casallas, FC; Fajardo Gomez, CA; García Gutiérrez, A; Herrera Castillo, DY; Roldan, F; Tamayo-Figueroa, DP, 2023
)
2.59
"Pentaerythritol tetranitrate (PETN) is an explosive chemical that has been detected in environmental media. "( Reproductive and developmental effects and physical and chemical properties of pentaerythritol tetranitrate (PETN) in the rat.
Crouse, LC; Johnson, MS; LaFiandra, EM; McFarland, CA; Quinn, MJ, 2009
)
2.02
"Pentaerythritol tetranitrate is an organic nitrate ester that undergoes metabolization to pentaerythritol, pentaerythritol trinitrate, pentaerythritol dinitrate and pentaerythritol mononitrate. "( Effects of nonintermittent treatment of rabbits with pentaerythritol tetranitrate on vascular reactivity and superoxide production.
Hacker, A; Kojda, G; Noack, E, 1998
)
1.99
"Pentaerythritol tetranitrate is an organic nitrate that has been used in the therapy of angina."( Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: a human in vivo study.
Babaei, S; Gori, T; Jurt, U; Parker, JD; Ravandi, A; Zeman, P, 2001
)
1.34

Effects

Pentaerythritol tetranitrate (PETN) is probably the only organic "tolerance-sparing" nitrate. PETN has been shown to release nitric oxide without development of nitrate tolerance.

ExcerptReferenceRelevance
"Pentaerythritol tetranitrate (PETN) has been shown to release nitric oxide without development of nitrate tolerance."( The nitric oxide donor pentaerythritol tetranitrate reduces platelet activation in congestive heart failure.
Bauersachs, J; Flierl, U; Fraccarollo, D; Micka, J; Neuser, J; Schäfer, A; Widder, JD, 2015
)
1.45
"Pentaerythritol tetranitrate (PETN) has raised a great deal of interest in recent years, because it is probably the only organic "tolerance-sparing" nitrate. "( [Clinical evaluation of pentaerythritol tetranitrate in two doses in patients with stable angina pectoris].
Kośmicki, MA; Malczewska, B; Sadowski, Z, 2005
)
2.08

Treatment

ExcerptReferenceRelevance
"Pentaerythritol tetranitrate (PETN) treatment reduces progression of atherosclerosis and endothelial dysfunction and decreases oxidation of low-density lipoprotein (LDL) in rabbits. "( Pharmacological induction of vascular extracellular superoxide dismutase expression in vivo.
Adams, V; Balz, V; Bas, M; Dao, VT; Kojda, G; Oppermann, M; Suvorava, T, 2009
)
1.8

Toxicity

ExcerptReferenceRelevance
" In the 2-year studies, there were no adverse effects on survival or body weight gains in either sex of rats or mice."( No evidence of toxicity or carcinogenicity of pentaerythritol tetranitrate given in the diet to F344 rats and B6C3F1 mice for up to two years.
Bucher, JR; Eustis, SL; Haseman, JK; Huff, J; Lilja, HS; Murthy, AS, 1990
)
0.54
"The aim of this study was the comparative evaluation of antianginal efficacy and the adverse effects of 3 nitrates in oral doses: isosorbide dinitrate 80 mg in slow release form (ISDN-80), nitroglycerin 15 mg--slow release (NITRO-15) and pentaerythritol tetranitrate 100 mg in normal tablets (PENTA-100) in patients (pts) with stable angina pectoris."( [Comparative evaluation of the clinical effectiveness and the adverse effects of three different forms of nitrates in high oral doses in patients with stable angina pectoris].
Jedrzejczyk, B; Kośmicki, M; Kowalik, I; Sadowski, Z, 2002
)
0.5
" The headaches, the most frequent adverse effects, occurred after ingestion of ISDN-80 in 6 pts, NITRO-15 in 4 pts, PENTA-100 in 3 pts and P in 1 pt."( [Comparative evaluation of the clinical effectiveness and the adverse effects of three different forms of nitrates in high oral doses in patients with stable angina pectoris].
Jedrzejczyk, B; Kośmicki, M; Kowalik, I; Sadowski, Z, 2002
)
0.31

Pharmacokinetics

ExcerptReferenceRelevance
" These drugs must be administered parenterally and have a half-life of only a few minutes."( Clinical pharmacokinetics of vasodilators. Part II.
Heintz, B; Kirsten, D; Kirsten, R; Nelson, K, 1998
)
0.3

Compound-Compound Interactions

ExcerptReferenceRelevance
" A study undertaken in dogs has also been made of the pharmacokinetics of the major nitrated metabolite of PETN when the parent drug is administered with and without meprobamate and diphenhydramine."( A study of the plasma levels of pentaerythritol mononitrate following administration of pentaerythritol tetranitrate in combination with meprobamate and diphenhydramine.
Aylott, RI; Draffan, GH; Gilbert, JD; Sögtrop, HH, 1982
)
0.49
"Corona discharge ionization combined with ion mobility spectrometry-mass spectrometry (IMS-MS) was utilized to investigate five common explosives: cyclonite (RDX), trinitrotoluene (TNT), pentaerythritol tetranitrate (PETN), cyclotetramethylenetetranitramine (HMX), and 2,4-dinitrotoluene (DNT)."( Analysis of explosives using corona discharge ionization combined with ion mobility spectrometry-mass spectrometry.
Cho, SG; Goh, EM; Kim, J; Koh, SS; Lee, J; Lee, S; Park, S, 2014
)
0.59

Bioavailability

ExcerptReferenceRelevance
" The oral bioavailability of 1 was in the range of 0-8%."( Pharmacokinetics of pentaerythritol tetranitrate following intra-arterial and oral dosing in the rat.
Fung, HL; King, SY, 1986
)
0.59
" The specific and sensitive HPLC-TEA method developed in this study provides a reliable and rapid assay for the routine analysis for metabolism or bioavailability studies of nitrate esters and their metabolites in plasma of blood, with a detection limit as low as 1 ng ml-1."( Measurement of plasma concentrations of vasodilators and metabolites by the TEA Analyzer.
Goff, EU; Yu, WC,
)
0.13
" The bioavailability of meprobamate administered rectally to human volunteers as the marketed preparations DoloVisano Suppositories and Dolo-Visano Suppositories sine codeino, is similar to that observed following oral administration."( The pharmacokinetics of meprobamate following its oral and rectal administration as a series of combinations with diphenhydramine, acetylsalicylic acid, codeine and pentaerythritol tetranitrate.
Aylott, RI; Draffan, GH; Gilbert, JD; Sögtrop, HH, 1984
)
0.46
" The relative bioavailability of the tablets as determined by means of the AUC of PE-di-N is 280-290%."( Pharmacokinetics and bioavailability of pentaerithrityl tetranitrate and two of its metabolites.
Kuntze, U; Luckow, V; Michaelis, K; Stalleicken, D; Weber, W, 1995
)
0.29
" The missing systemic bioavailability of PETN and PEtriN may explain the discrepancy between in vitro and in vivo findings."( Potency and in vitro tolerance of organic nitrates: partially denitrated metabolites contribute to the tolerance-devoid activity of pentaerythrityl tetranitrate.
Daiber, A; Glusa, E; Koenig, A; Konter, J; Lange, K; Lehmann, J; Stalleicken, D, 2007
)
0.34
" Increased expression and activity of microvascular ecSOD are likely induced by increased bioavailability of vascular nitric oxide."( Pharmacological induction of vascular extracellular superoxide dismutase expression in vivo.
Adams, V; Balz, V; Bas, M; Dao, VT; Kojda, G; Oppermann, M; Suvorava, T, 2009
)
0.35
"The status of nitric oxide (NO) in spontaneously hypertensive rats (SHR) is unclear and its bioavailability may be affected by imbalance with reactive oxygen species."( The effect of an NO donor, pentaerythrityl tetranitrate, on biochemical, functional, and morphological attributes of cardiovascular system of spontaneously hypertensive rats.
Cacányiová, S; Dovinová, I; Fáberová, V; Kristek, F, 2009
)
0.35
"Organic nitrates represent a class of drugs which are clinically used for treatment of ischemic symptoms of angina as well as for congestive heart failure based on the idea to overcome the impaired NO bioavailability by "NO" replacement therapy."( Organic nitrates and nitrate resistance in diabetes: the role of vascular dysfunction and oxidative stress with emphasis on antioxidant properties of pentaerithrityl tetranitrate.
Daiber, A; Oelze, M; Schuhmacher, S, 2010
)
0.36
"Reduced nitric oxide bioavailability contributes to progression of cardiac dysfunction and remodeling in ischemic heart failure."( Pentaerythritol Tetranitrate Targeting Myocardial Reactive Oxygen Species Production Improves Left Ventricular Remodeling and Function in Rats With Ischemic Heart Failure.
Bauersachs, J; Fraccarollo, D; Galuppo, P; Neuser, J; Widder, JD, 2015
)
1.86
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" A solution of powder is made directly from the dosage form in glacial acetic acid and is then reacted with phenoldisulfonic acid TS."( Modified NF method for quantitative determination of pentaerythritol tetranitrate.
Gupta, VD, 1978
)
0.51
"Intact pentaerythritol (PE) tetranitrate and all seven of its metabolites were present in blood withdrawn from the hearts of rats dosed by gavage with 14-C-PE tetranitrate (10 mg/kg)."( Pentaerythritol tetranitrate and metabolites in rat plasma.
Crew, M; Di Carlo, FJ; Melgar, MD, 1975
)
1.7
" In own long-term studies on 34 patients with coronary heart disease with clinical and haemodynamic evidence (pathologic increase of the end-diastolic pressure of the pulmonary arteries under ergometric load) of an exercise-induced heart insufficiency the efficacy of pentaerythril tetranitrate (PETN) and isosorbide dinitrate (ISDN) in chronic dosage titration use was tested."( [Long-term nitrate therapy in coronary heart disease--loss of effect by developing tolerance].
Dück, KD; Richard, F, 1990
)
0.28
" The trinitrate derivative (2,2-bis(hydroxymethyl)-1,3-propanediol trinitrate, 2) the active metabolite of 1, was not detectable following oral dosing with the tetranitrate."( Pharmacokinetics of pentaerythritol tetranitrate following intra-arterial and oral dosing in the rat.
Fung, HL; King, SY, 1986
)
0.59
" The metabolic profiles of PETN in rat urine and feces following intra-arterial and oral dosing of this organic nitrate were then re-examined."( Rapid microbial degradation of organic nitrates in rat excreta. Re-examination of the urinary and fecal metabolite profiles of pentaerythritol tetranitrate in the rat.
Fung, HL; King, SY,
)
0.34
" The long duration of action (at least 8 hours) allows prolonged dosage intervals."( [Prolonged hemodynamic effects of pentaerythrityl tetranitrate combined with piridoxylate].
Baudet, M; Hericotte, P, 1983
)
0.27
"A reliable, sensitive, and specific assay for isosorbide dinitrate pentaerythritol tetranitrate, and erythrityl tetranitrate in sublingual, uncoated, sustained-release, and chewable dosage forms, using high-performance liquid chromatography, is described."( High-performance liquid chromatographic determination of the nitrate esters isosorbide dinitrate, pentaerythritol tetranitrate, and erythrityl tetranitrate in various tablet forms.
Olsen, CS; Scroggins, HS, 1984
)
0.72
" In a small group of angina patients, the oral nitrate in high dosage resulted in considerable increase in angina-limited exercise capacity compared to placebo for four hours following drug administration."( Effects of oral pentaerythritol tetranitrate in cardiac failure and angina pectoris. Assessment by hemodynamic measurement and exercise capacity.
Amsterdam, EA; Awan, NA; Lee, G; Low, R; Mason, DT, 1980
)
0.61
"Neither therapeutic dosage of nitrovasodilators nor the development of tolerance correlates with nitrate groups in these molecules."( Potency and in vitro tolerance of organic nitrates: partially denitrated metabolites contribute to the tolerance-devoid activity of pentaerythrityl tetranitrate.
Daiber, A; Glusa, E; Koenig, A; Konter, J; Lange, K; Lehmann, J; Stalleicken, D, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
explosiveA substance capable of undergoing rapid and highly exothermic decomposition.
vasodilator agentA drug used to cause dilation of the blood vessels.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pentaerythritol nitrate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency10.71350.000221.22318,912.5098AID743035; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency1.58490.011212.4002100.0000AID1030
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency37.90830.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency26.83250.000214.376460.0339AID720692
pregnane X nuclear receptorHomo sapiens (human)Potency27.30600.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency5.57920.000229.305416,493.5996AID743069; AID743075; AID743080
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency4.77160.001019.414170.9645AID743094
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency24.33650.001723.839378.1014AID743083
Cellular tumor antigen p53Homo sapiens (human)Potency14.96010.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID352262Vasorelaxant activity in pig pulmonary artery by organ bath experiment2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
NO donors. Part 18: Bioactive metabolites of GTN and PETN--synthesis and vasorelaxant properties.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (478)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990266 (55.65)18.7374
1990's28 (5.86)18.2507
2000's73 (15.27)29.6817
2010's63 (13.18)24.3611
2020's48 (10.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.49 (24.57)
Research Supply Index6.35 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index76.15 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (46.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials70 (14.03%)5.53%
Reviews25 (5.01%)6.00%
Case Studies14 (2.81%)4.05%
Observational1 (0.20%)0.25%
Other389 (77.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]